Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference
Amarin Corporation (NASDAQ:AMRN) has announced that its CEO, John F. Thero, will present at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, from 11:20 to 11:50 a.m. ET. A live audio webcast of the presentation will be accessible on the company's investor relations website and available for 30 days post-event.
Amarin is focused on developing therapeutics for cardiovascular health, with its primary product, VASCEPA (icosapent ethyl), currently available in select countries. The company is seeking further regulatory approvals for VASCEPA in various regions.
- None.
- None.
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 from 11:20 - 11:50 a.m. Eastern Time.
A live audio webcast of the presentation will be available at: http://investor.amarincorp.com/ and will be accessible at the same link for 30 days.
About Amarin
Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. VASCEPA is not yet approved and available in any other countries. Amarin, on its own or together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, Europe and the Middle East. For more information about Amarin, visit www.amarincorp.com.
Availability of other Information about Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Elisabeth Schwartz
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
IR@amarincorp.com (investor inquiries)
Lee M. Stern
Solebury Trout
In U.S.: +1 (646) 378-2992
lstern@soleburytrout.com
Media Inquiries:
Alina Kolomeyer
Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
PR@amarincorp.com (media inquiries)
FAQ
When is Amarin's presentation at the 2020 Cantor Virtual Global Healthcare Conference?
Where can I watch the Amarin Corporation presentation?
What is VASCEPA and where is it available?
Is VASCEPA approved in other countries?
What is Amarin Corporation focused on?
